Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

St. Jude Medical Wins European Approval for Prodigy System

By Eric Volkman - Mar 20, 2014 at 6:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

St. Jude Medical launches its chronic pain-relieving system on the continent.

St. Jude Medical ( STJ ) has launched its latest product on the European market. The company announced that it has received the CE Mark for its Prodigy Chronic Pain System with Burst Technology and can now market and sell the product on the continent.

St. Jude Medical claims that Prodigy is "the first and only implantable neuromodulation system that delivers burst stimulation." It is intended to reduce pain and reduce parasthesia, a tingling sensation, in patients suffering from chronic pain. It utilizes spinal cord stimulation to achieve its effects.

In the press release announcing the news, the company quoted its Group President Eric Fain as saying that Prodigy "is a great example of our approach for innovative and alternative ways to provide relief to patients suffering from chronic pain, including those who have exhausted other treatment options or who may have lost effective therapy using traditional tonic stimulation."

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

St. Jude Medical, Inc. Stock Quote
St. Jude Medical, Inc.
STJ

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/05/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.